Loading
companiesCompany
Mersana Therapeutics
ADC platform company betting on B7-H4: emiltatug ledadotin (Emi-Le) has Breakthrough designation in adenoid cystic carcinoma and activity in TNBC after TOP1 ADCs.
Overview
Mersana Therapeutics, based in Cambridge, Massachusetts, and listed as MRSN, is an antibody-drug conjugate platform company betting on B7-H4, whose emiltatug ledadotin, or Emi-Le, holds Breakthrough designation in adenoid cystic carcinoma and shows activity in triple-negative breast cancer after topoisomerase 1 ADCs. Emi-Le, also XMT-1660, produced a 23 percent objective response rate in TNBC previously treated with topoisomerase 1 ADCs and confirmed responses in adenoid cystic carcinoma, earning Breakthrough designation in May 2026, and the company also pioneered STING-agonist ADCs such as XMT-2056. OnCo links it to TNBC, head and neck, ovarian and endometrial cancer, to ADC sequencing as a term, and to the bottleneck of acquired resistance. Whether a non-topoisomerase payload can rescue patients after TOP1 ADCs fail is the open question.
Headquarters
Cambridge, MA, US
Scorecard
All companies#466of 1244 companies, score 6
- phase 1/2 +1
- modalities +2
- registry trials +3
0 approved, 0 in phase 3, 1 earlier, 0 targets, 2 registry studies. Formula on the scorecards page.
Type
Biotech · MRSN
Stage
Public
Website
Phase 2Antibody-drug conjugate
Upifitamab rilsodotin is an antibody-drug conjugate from Mersana Therapeutics, in registered phase 2 trials for ovarian cancer, non-small-cell lung cancer.
Similar pages
- CompanyTallac Therapeutics
Shares Immune-stimulating antibody conjugate (ISAC), Antibody-drug conjugate (ADC).
- CompanyNBE-Therapeutics
Shares Immune-stimulating antibody conjugate (ISAC), Antibody-drug conjugate (ADC).
- IdeaUse SLFN11 status to decide which antibody-drug payload to give next
Shares ADC sequencing, Acquired resistance to every therapy, Antibody-drug conjugate (ADC).
- IdeaRandomise the next line of treatment before the first one fails
Shares ADC sequencing, Acquired resistance to every therapy.
- IdeaSequential multiple-assignment randomised trials to find the best order of ADCs
Shares ADC sequencing, Acquired resistance to every therapy, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).
- IdeaPayload-class switching as the rule for ADC sequencing
Shares ADC sequencing, Acquired resistance to every therapy, Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC).
- RoadmapADC roadmap: from Mylotarg to bispecific and dual-payload ADCs
Shares Immune-stimulating antibody conjugate (ISAC), ADC sequencing, Antibody-drug conjugate (ADC), Ovarian cancer.
- CompanySutro Biopharma
Shares Acquired resistance to every therapy, Antibody-drug conjugate (ADC), Ovarian cancer.
cancers
fronts
technologies
drugs
Phase 2Antibody-drug conjugate